
## **Giuseppe Lopalco**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9347951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews, 2021, 20, 102763.	2.5	140
2	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 191-197.	1.0	115
3	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Tj ETQq1 1 956-964.	0.784314 0.8	rgBT /Overloc 98
4	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	1.0	95
5	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
6	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 183-189.	1.0	84
7	Safety of longâ€ŧerm biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology, 2015, 62, 40-46.	3.6	82
8	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-21.	1.4	79
9	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmunity Reviews, 2015, 14, 1-9.	2.5	79
10	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306.	2.9	78
11	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
12	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clinical Rheumatology, 2017, 36, 463-468.	1.0	64
13	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
14	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. Journal of Clinical Medicine, 2018, 7, 504.	1.0	61
15	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. International Journal of Molecular Sciences, 2019, 20, 1898.	1.8	60
16	Key facts and hot spots on tumor necrosis factor receptorâ€associated periodic syndrome. Clinical Rheumatology, 2014, 33, 1197-1207.	1.0	58
17	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clinical Rheumatology, 2019, 38, 407-415.	1.0	56
18	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity Reviews, 2015, 14, 90-97.	2.5	55

#	Article	IF	CITATIONS
19	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmunity Reviews, 2016, 15, 447-450.	2.5	54
20	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 451-455.	1.0	52
21	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. Medicine (United States), 2015, 94, e1528.	0.4	51
22	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clinical Rheumatology, 2015, 34, 1141-1143.	1.0	51
23	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. Frontiers in Immunology, 2017, 8, 200.	2.2	50
24	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	1.0	48
25	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. Ocular Immunology and Inflammation, 2020, 28, 298-304.	1.0	46
26	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. British Journal of Ophthalmology, 2018, 102, 637-641.	2.1	44
27	Influence of baseline modified Rheumatic Disease Comorbidity Index ( <scp>mRDCI</scp> ) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in realâ€world settings. European Journal of Clinical Investigation, 2018, 48, e13013.	1.7	42
28	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	41
29	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular BehA§et's phenotype: a multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1098-1104.	0.5	39
30	Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. Modern Rheumatology, 2017, 27, 1031-1035.	0.9	38
31	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. Rheumatology International, 2019, 39, 971-990.	1.5	38
32	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clinical Rheumatology, 2015, 34, 17-28.	1.0	37
33	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. Ocular Immunology and Inflammation, 2019, 27, 34-39.	1.0	37
34	New therapeutic solutions for Behçet's syndrome. Expert Opinion on Investigational Drugs, 2016, 25, 827-840.	1.9	36
35	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clinical Rheumatology, 2017, 36, 2063-2069.	1.0	36
36	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clinical Rheumatology, 2018, 37, 2805-2809.	1.0	35

#	Article	IF	CITATIONS
37	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
38	IL-6 blockade in the management of non-infectious uveitis. Clinical Rheumatology, 2017, 36, 1459-1469.	1.0	33
39	COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatology International, 2020, 40, 827-828.	1.5	33
40	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. Medicine (United States), 2015, 94, e1858.	0.4	31
41	Canakinumab efficacy in refractory adultâ€onset <scp>PFAPA</scp> syndrome. International Journal of Rheumatic Diseases, 2017, 20, 1050-1051.	0.9	31
42	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. Trends in Cardiovascular Medicine, 2021, 31, 265-274.	2.3	31
43	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	30
44	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Current Cardiology Reports, 2018, 20, 61.	1.3	29
45	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clinical Rheumatology, 2019, 38, 63-70.	1.0	29
46	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	29
47	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	1.0	28
48	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	1.0	28
49	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators of Inflammation, 2019, 2019, 1-8.	1.4	27
50	Interleukin-1 Inhibition in Behçet's disease. Israel Medical Association Journal, 2016, 18, 171-6.	0.1	26
51	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	25
52	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
53	Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials. Pain Research and Treatment, 2017, 2017, 1-12.	1.7	24
54	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease. Immunology Letters, 2018, 201, 38-44.	1.1	24

#	Article	IF	CITATIONS
55	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology, 2020, 59, 1599-1606.	0.9	24
56	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- <i>α</i> Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	24
57	A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study. Internal and Emergency Medicine, 2021, 16, 1457-1465.	1.0	23
58	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clinical and Experimental Rheumatology, 2016, 34, 531-8.	0.4	23
59	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	22
60	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. Clinical Rheumatology, 2016, 35, 2363-2367.	1.0	22
61	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 103-108.	0.9	22
62	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. Clinical Rheumatology, 2018, 37, 1715-1720.	1.0	21
63	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. Annals of the Rheumatic Diseases, 2019, 78, 1736-1737.	0.5	21
64	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
65	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. Clinical and Experimental Rheumatology, 2016, 34, 77-81.	0.4	21
66	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clinical Rheumatology, 2015, 34, 1503-1511.	1.0	20
67	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clinical Rheumatology, 2015, 34, 807-809.	1.0	20
68	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). RMD Open, 2020, 6, e001192.	1.8	20
69	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5.	1.4	20
70	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. Journal of Rheumatology, 2016, 43, 911-917.	1.0	19
71	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. Frontiers in Pharmacology, 2019, 10, 1468.	1.6	19
72	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. Inflammopharmacology, 2020, 28, 711-718.	1.9	19

#	Article	IF	CITATIONS
73	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	3.1	19
74	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open, 2022, 8, e001847.	1.8	19
75	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clinical and Experimental Rheumatology, 2019, 37, 680-683.	0.4	19
76	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. Mediators of Inflammation, 2020, 2020, 1-7.	1.4	18
77	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. Israel Medical Association Journal, 2015, 17, 93-7.	0.1	18
78	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Israel Medical Association Journal, 2016, 18, 238-42.	0.1	18
79	Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	16
80	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clinical Rheumatology, 2015, 34, 1171-1180.	1.0	15
81	Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology International, 2018, 38, 25-35.	1.5	15
82	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 1309-1317.	1.0	15
83	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2018, 9, 1526.	1.6	15
84	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	15
85	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. Clinical and Experimental Rheumatology, 2018, 36, 68-73.	0.4	15
86	Serum amyloid-A in Behçet's disease. Clinical Rheumatology, 2014, 33, 1165-1167.	1.0	14
87	Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Multiple Sclerosis and Related Disorders, 2020, 42, 102152.	0.9	14
88	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine, 2021, 88, 105062.	0.8	14
89	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.5	14
90	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Ophthalmology and Therapy, 2022, 11, 899-911.	1.0	14

#	Article	IF	CITATIONS
91	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. Internal and Emergency Medicine, 2019, 14, 719-722.	1.0	13
92	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine, 2020, 15, 1031-1039.	1.0	13
93	Longâ€term efficacy and safety of the interleukinâ€1 inhibitors anakinra and canakinumab in refractory BehA§et disease uveitis and concomitant bladder papillary carcinoma. Internal Medicine Journal, 2017, 47, 1086-1088.	0.5	11
94	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clinical and Experimental Rheumatology, 2016, 34, 424-9.	0.4	11
95	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. Internal and Emergency Medicine, 2016, 11, 781-791.	1.0	10
96	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clinical Rheumatology, 2016, 35, 19-23.	1.0	10
97	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clinical and Experimental Rheumatology, 2019, 37, 762-767.	0.4	10
98	Management of Small Vessel Vasculitides. Current Rheumatology Reports, 2016, 18, 36.	2.1	9
99	Rapid desensitization to anakinraâ€related delayed reaction: Need for a standardized protocol. Journal of Dermatology, 2017, 44, 981-982.	0.6	9
100	Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics. Clinical Rheumatology, 2017, 36, 445-449.	1.0	9
101	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatology, 2020, 59, 1188-1188.	0.9	9
102	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. Ophthalmology and Therapy, 2022, 11, 887-897.	1.0	9
103	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. Journal of Personalized Medicine, 2022, 12, 353.	1.1	9
104	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9
105	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. Frontiers in Immunology, 2022, 13, 860877.	2.2	9
106	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Annals of the Rheumatic Diseases, 2022, 81, 1769-1772.	0.5	9
107	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. Internal and Emergency Medicine, 2021, 16, 2163-2171.	1.0	8
108	Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. Clinical and Experimental Rheumatology, 2019, 37, 301-305.	0.4	8

#	Article	IF	CITATIONS
109	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clinical and Experimental Rheumatology, 2021, 39, 187-195.	0.4	8
110	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. Arthritis Research and Therapy, 2020, 22, 278.	1.6	7
111	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. Clinical and Experimental Rheumatology, 2016, 34, 353.	0.4	7
112	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. Clinical and Experimental Rheumatology, 2017, 35, 93-97.	0.4	7
113	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. Israel Medical Association Journal, 2017, 19, 415-419.	0.1	7
114	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. Israel Medical Association Journal, 2018, 20, 438-441.	0.1	7
115	Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. Joint Bone Spine, 2014, 81, 458-459.	0.8	6
116	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. Journal of Clinical Rheumatology, 2020, 26, e208-e209.	0.5	6
117	Safety of systemic treatments for Behçet's syndrome. Expert Opinion on Drug Safety, 2020, 19, 1269-1301.	1.0	6
118	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. Clinical and Experimental Immunology, 2020, 201, 200-204.	1.1	6
119	Predictors of longâ€ŧerm clinical remission in rheumatoid arthritis. European Journal of Clinical Investigation, 2021, 51, e13363.	1.7	6
120	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	1.2	6
121	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S171-2.	0.4	6
122	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. Frontiers in Medicine, 2021, 8, 769870.	1.2	6
123	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227-227.	0.4	6
124	A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab. Frontiers in Immunology, 0, 13, .	2.2	6
125	Retinal Vessels Thrombosis as Onset Manifestation of Systemic Sclerosis: 3 Clinical Cases. Journal of Rheumatology, 2014, 41, 2495-2496.	1.0	5
126	Delights and letâ€downs in the management of tumor necrosis factor receptorâ€associated periodic syndrome: the canakinumab experience in a patient with a highâ€penetrance T50M <i><scp>TNFRSF</scp>1A</i> variant. International Journal of Rheumatic Diseases, 2015, 18, 473-475.	0.9	5

#	Article	IF	CITATIONS
127	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 130-131.	0.4	5
128	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. Reumatismo, 2014, 65, 298.	0.4	4
129	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. Rheumatology, 2019, 58, 440-440.	0.9	4
130	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2020, 79, e104-e104.	0.5	4
131	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	0.9	4
132	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. Joint Bone Spine, 2022, 89, 105299.	0.8	4
133	Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 1138-1144.	0.4	4
134	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. Pediatric Rheumatology, 2015, 13, .	0.9	3
135	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.3	3
136	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2021, 27, e73-e74.	0.5	3
137	OP0148â€MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTI REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 94-95.	VE 0.5	3
138	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. Israel Medical Association Journal, 2018, 20, 517-521.	0.1	3
139	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, ,	0.4	3
140	Refractory knee giant cell tumor of the synovial membrane treated with intraâ€articular injection of Infliximab: a case series and review of the literature. International Journal of Rheumatic Diseases, 2015, 18, 908-912.	0.9	2
141	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwinding obesity and osteoarthritis?. Annals of the Rheumatic Diseases, 2015, 74, e70-e70.	0.5	2
142	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. Clinical Rheumatology, 2021, 40, 3659-3665.	1.0	2
143	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. Internal and Emergency Medicine, 2022, 17, 475-480.	1.0	2
144	Complete Hydatidiform Mole Mimicking Sacroiliitis. Journal of Clinical Rheumatology, 2021, 27, e122-e122.	0.5	2

#	Article	IF	CITATIONS
145	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Clinical and Experimental Rheumatology, 2017, 35, 170-171.	0.4	2
146	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. Reumatismo, 2015, 67, 17-20.	0.4	1
147	SAT0216â€Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings. Annals of the Rheumatic Diseases, 2016, 75, 747.1-747.	0.5	1
148	AB0037â€Serum cytokine signature in mucocutaneous and ocular behÇet's disease. , 2017, , .		1
149	AB0709â€Switching from originator infliximab to biosimilar infliximab: efficacy and safety in a cohort of patients with established behÇet's disease. , 2018, , .		1
150	287. TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. Rheumatology, 2019, 58, .	0.9	1
151	AB0608â€TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. , 2019, , .		1
152	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	1.2	1
153	OP0093â€RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER'S SYNDROME. Annals of th Rheumatic Diseases, 2021, 80, 51-52.	e <sub>0.5</sub>	1
154	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 227.	0.4	1
155	AB0065â€Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease. Annals of the Rheumatic Diseases, 2015, 74, 912.2-912.	0.5	0
156	AB0452â€Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 1046.3-1047.	0.5	0
157	SAT0384â€Long-Term Safety of Anti-Tnf Agents in Patients with Spondyloarthritis and Potential Occult HBV: An Observational Multicenter Study on 131 Patients. Annals of the Rheumatic Diseases, 2016, 75, 807.1-807.	0.5	0
158	THU0540â€Efficacy and safety of adalimumab in behÇet's disease related uveitis: a multicenter retrospective observational study. , 2017, , .		0
159	AB1160â€Epidemiology and clinical presentation of ocular involvement in a population of 278 patients with non infectious uveitis. , 2017, , .		0
160	SAT0616â€Ten-year retention rate of infliximab in patients with behÇet's disease-related uveitis. , 2018, , .		0
161	THU0299â€PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇET'S SYNDROME: A MULTICENTE STUDY. , 2019, , .	ER	0
162	SAT0380â€FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS. , 2019, , .		0

#	Article	CITATIONS
163	AB0245â€PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .	0
164	SAT0240â€DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇET'S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .	0
165	AB0600â€APREMILAST EFFECTIVENESS IN REFRACTORY ORAL AND GENITAL ULCERS OF BEHÇET'S DISEASE: DAT FROM REAL LIFE SETTINGS. , 2019, , .	A o
166	AB0640â€SURVIVAL AND MORTALITY PREDICTORS IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC ITALIAN COHORT. , 2019, , .	0
167	FRI0070â€SHORT-TERM INFLAMMATORY AND LIPIDS CHANGES IN RHEUMATOID ARTHRITIS PATIENTSINFLUENCE CARDIOVASCULAR RISK ALGORITHMS: A MONOCENTRIC RETROSPECTIVE STUDY. , 2019, , .	Ο
168	Response to: †Response to: †@Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients―by 0.5 Fornaro et al†™ by Agca et al. Annals of the Rheumatic Diseases, 2020, 79, e106-e106.	0
169	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2020, 26, e102-e102.	Ο
170	ABO380â€MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERING. Annals of the Rheumatic Diseases, 2021, 80, 1217-1217.	0
171	POS0631â€COMPARATIVE EFFICACY OF COMBINATION THERAPY WITH BIOLOGIC OR TARGET SYNTHETIC DRUGS FOR RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS. Annals of the Rheumatic Diseases, 0.5 2021, 80, 553.2-554.	Ο
172	Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF). Joint Bone Spine, 0.8 2022, 89, 105259.	0
173	THU0153â€The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients. , 2018, , .	ο
174	AB0836â€Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study. , 2018, , .	0
175	AB0369â€Adult-onset still's disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience. , 2018, , .	Ο
176	SAT0307â€Impact of the modified rheumatic disease comorbidity index(MRDCI) on drug survival of first line anti-tnfl drugs in patents affected with psoriatic arthritis in real life setting. , 2018, , .	0
177	OP0129â€Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors. , 2018, , .	Ο
178	THU0168â€Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis. , 2018, , .	0
179	SAT0605â€The presence of uveitis predicts the response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in behÇet's disease. , 2018, , .	Ο
180	FRI0075â€Risk of hepatitis b infection reactivation in rheumatic diseases patients treated with anti-cd20 therapy. , 2018, , .	0

#	Article	IF	CITATIONS
181	AB0844â€SERUM sCD40L LEVEL CAN PREDICT SHORT-TERM CLINICAL OUTCOMES IN PATIENTS WITH PSORIAT ARTHRITIS ON TREATMENT WITH APREMILAST Annals of the Rheumatic Diseases, 2020, 79, 1728-1729.	ဂၢင္ပ ၂.5	0
182	Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema. Clinical and Experimental Rheumatology, 2020, 38, 621-625.	0.4	0
183	Reply to Praprotnik and Tomsic and erratum corrige. Clinical and Experimental Rheumatology, 2020, 38, 1034.	0.4	0
184	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. Clinical and Experimental Rheumatology, 2021, 39, 1147-1148.	0.4	0
185	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2018, 26, 1.	0.5	0
186	Retention rate of IL-1 inhibitors in Schnitzler's syndrome Clinical and Experimental Rheumatology, 2022, , .	0.4	0